Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease. METHODS: vg per kilogram). The primary outcome was safety. The secondary outcome was the time until death or the need for permanent ventilatory assistance. In exploratory analyses, we compared scores on the CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale of motor function (ranging from 0 to 64, with higher scores indicating better function) in the two cohorts and motor milestones in the high-dose cohort with scores in studies of the natural history of the disease (historical cohorts). RESULTS: As of the data cutoff on August 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared with a rate of survival of 8% in a historical cohort. In the high-dose cohort, a rapid increase from baseline in the score on the CHOP INTEND scale followed gene delivery, with an increase of 9.8 points at 1 month and 15.4 points at 3 months, as compared with a decline in this score in a historical cohort. Of the 12 patients who had received the high dose, 11 sat unassisted, 9 rolled over, 11 fed orally and could speak, and 2 walked independently. Elevated serum aminotransferase levels occurred in 4 patients and were attenuated by prednisolone. CONCLUSIONS: In patients with SMA1, a single intravenous infusion of adeno-associated viral vector containing DNA coding for SMN resulted in longer survival, superior achievement of motor milestones, and better motor function than in historical cohorts. Further studies are necessary to confirm the safety and efficacy of this gene therapy. (Funded by AveXis and others; ClinicalTrials.gov number, NCT02122952 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, the FDA has approved AAV for gene replacement therapy in spinal muscular atrophy and congenital blindness, and clinical trials are in progress 58 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [58]
In the citing paper
“preclinical and clinical studies have demonstrated dose-dependent inflammation, which can reduce efficacy and lead to dose-limiting toxicity (2–8)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [4]
In the citing paper
“Although neuroimaging is typically more expensive than EEG and studies are limited by issues of replication, sometimes that is related to head motion that occurred during the scan which can erode signal 61”
From Autism spectrum disorder (2020) · cites this paper as [61]
In the citing paper
“Especially considering the ability of the recombinant AAV genome to persist as an episome in post-mitotic cells, such as neurons, which ensures long-term expression even after a single administration [130-132].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [132]
In the citing paper
“With AAV9’s inherent ability to target motor neurons, AAV9-based Zolgensma® for the treatment of SMA has been established as the first FDA-approved drug for systemic gene therapy in CNS diseases [171].”
From Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside (2024) · cites this paper as [171]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
Self-citationRetractedDeaths: preliminary data for 2003.
Hoyert, D. L., Kung, H.-C., & Smith, B. L. (2005) · PubMed · Cited by 1,649
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Self-citationBayley Scales of Infant and Toddler Development, Third Edition
Bayley, N. (2012) · PsycTESTS Dataset · doi:10.1037/t14978-000 · Cited by 1,175
National Vital Statistics Reports NCHS.pdf
Hoyert, D. (2012) · Medical Entomology and Zoology · Cited by 982
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961 · cited 4×
“Viral upper respiratory tract infection 0 0 3 3 (25) 3 3 (20)”
InfluentialAntisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664
Sugarman, E. A., Nagan, N., Zhu, H., Akmaev, V. R., Zhou, Z., Rohlfs, E. M., Flynn, K., Hendrickson, B. C., Scholl, T., Sirko-Osadsa, D. A., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.134 · Cited by 661
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
de Onis, M., Onyango, A. W., Van den Broeck, J., Chumlea, W. C., & Martorell, R. (2004) · Food and Nutrition Bulletin · doi:10.1177/15648265040251s105 · Cited by 529
Research works printed but not linked: 1
- Hoyert DL, 2012, Natl Vital Stat Rep, 61, 1
Cited by
Items 401–500 of 1,005
Efficacy of gene delivery to the brain using AAV and ultrasound depends on serotypes and brain areas
Kofoed, R. H., Dibia, C. L., Noseworthy, K., Xhima, K., Vacaresse, N., Hynynen, K., & Aubert, I. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.048 · Cited by 67
Wang, D., Zhong, L., Li, M., Li, J., Tran, K., Ren, L., He, R., Xie, J., Moser, R. P., Fraser, C., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.09.003 · Cited by 53
In Situ Modification of Tissue Stem and Progenitor Cell Genomes
Goldstein, J. M., Tabebordbar, M., Zhu, K., Wang, L. D., Messemer, K. A., Peacker, B. L., Kakhki, S. A., Gonzalez-Celeiro, M., Shwartz, Y., Cheng, J. K. W., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.105 · Cited by 55
“…mice (Bengtsson et al., 2017; Chamberlain and Chamberlain, 2017; Long et al., 2016; Nelson et al., 2016; Tabebordbar et al., 2016; Yang et al., 2016) and canines (Amoasii et al., 2018), as well as those used in successful human trials for spinal muscular atrophy gene therapy (Mendell et al., 2017).”
Gao, Y., Irvine, E. E., Eleftheriadou, I., Naranjo, C. J., Hearn-Yeates, F., Bosch, L., Glegola, J. A., Murdoch, L., Czerniak, A., Meloni, I., et al. (2020) · Brain · doi:10.1093/brain/awaa028 · Cited by 61
Gene Therapy Corrects Brain and Behavioral Pathologies in CLN6-Batten Disease
Cain, J. T., Likhite, S., White, K. A., Timm, D. J., Davis, S. S., Johnson, T. B., Dennys-Rivers, C. N., Rinaldi, F., Motti, D., Corcoran, S., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.06.015 · Cited by 53
“This specific vector was chosen based on its CNS transduction efficiency and its proven safety in human subjects, as documented in a current phase I clinical trial for infants with type I spinal muscular atrophy.(22) After cloning, transgene mRNA and protein expressions were verified in vitro in HEK293 cells (Figure S…”
BackgroundMethodSelf-citationFuture Prospects of Gene Therapy for Friedreich’s Ataxia
Ocana-Santero, G., Díaz‐Nido, J., & Herranz-Martín, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041815 · Cited by 59
“5 kb Years Episomal Low Long-term only in non-dividing cells Approved Zolgensma [24,38]”
BackgroundInfluentialSplicing modulators: on the way from nature to clinic
Schneider‐Poetsch, T., Chhipi-Shrestha, J. K., & Yoshida, M. (2021) · The Journal of Antibiotics · doi:10.1038/s41429-021-00450-1 · Cited by 56
Leborgne, C., Latournerie, V., Boutin, S., Desgue, D., Quéré, A., Pignot, E., Collaud, F., Charles, S., Simon Sola, M., Masat, E., et al. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2018.03.004 · Cited by 53
“AAV gene transfer has resulted in several examples of success in human trials [7-14].”
BackgroundLackington, W. A., Raftery, R. M., & O’Brien, F. J. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.06.014 · Cited by 56
“While viral gene therapy for the correction of genetic disorders has led to recent successes[57-59], the main hurdle facing NV gene therapy for tissue engineering, and”
BackgroundKarakaya, M., Storbeck, M., Strathmann, E. A., Vedove, A. D., Hölker, I., Altmüller, J., Naghiyeva, L., Schmitz-Steinkrüger, L., Vezyroglou, A., Motameny, S., et al. (2018) · Human Mutation · doi:10.1002/humu.23560 · Cited by 56
“In the era of novel therapeutic options for 5q-SMA patients (Finkel, et al., 2017; Mendell et al., 2017), a correct genetic diagnosis is important.”
BackgroundDevelopment of an academic disease registry for spinal muscular atrophy
Mercuri, E. M., Finkel, R. S., Scoto, M., Hall, S. A., Eaton, S., Rashid, A., Balashkina, J., Coratti, G., Pera, M. C., Samsuddin, S., et al. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.08.014 · Cited by 56
MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients
Brogna, C., Cristiano, L., Verdolotti, T., Pichiecchio, A., Cinnante, C. M., Sansone, V., Sconfienza, L. M., Berardinelli, A. L., Garibaldi, M., Antonini, G., et al. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09646-w · Cited by 60
The Impact of Mitochondrial Deficiencies in Neuromuscular Diseases
Cantó-Santos, J., Grau-Junyent, J., & Garrabou, G. (2020) · Antioxidants · doi:10.3390/antiox9100964 · Cited by 46
Humoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
“The earliest clinical trials investigating SMA gene therapy via systemic delivery did not report the induction of antibodies against either the AAV9 capsid protein or the SMN-1 transgene (Mendell et al., 2017; Al-Zaidy et al., 2019; Lowes et al., 2019).”
Update in the Mucopolysaccharidoses
McBride, K. L., & Flanigan, K. M. (2021) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2021.100874 · Cited by 51
Dysphagia Phenotypes in Spinal Muscular Atrophy: The Past, Present, and Promise for the Future
McGrattan, K. E., Graham, R. J., DiDonato, C. J., & Darras, B. T. (2021) · American Journal of Speech-Language Pathology · doi:10.1044/2021_ajslp-20-00217 · Cited by 57
Konstantinidis, E., Molisak, A., Perrin, F., Streubel-Gallasch, L., Fayad, S., Kim, D. Y., Petri, K., Aryee, M. J., Aguilar, X., György, B., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.022 · Cited by 66
“In 2019 the FDA approved the fi rst ever gene therapy for a neurological disorder, spinal muscular atrophy, 36 and in 2020 the fi rst gene-editing clinical trial where CRISPR components were administered directly to patients entered its phase I stage against the rare eye disorder Leber ’ s congenital…”
Newborn Screening for Spinal Muscular Atrophy in New York State
Lee, B. H., Deng, S., Chiriboga, C. A., Kay, D. M., Irumudomon, O., Laureta, E. C., Delfiner, L., Treidler, S. O., Anziska, Y., Sakonju, A., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200986 · Cited by 54
Comprehensive Modeling of Spinal Muscular Atrophy in Drosophila melanogaster
Spring, A. M., Raimer, A. C., Hamilton, C. D., Schillinger, M. J., & Matera, A. G. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00113 · Cited by 65
Gene Replacement Therapy: A Primer for the Health-system Pharmacist
Petrich, J., Marchese, D., Jenkins, C., Storey, M., & Blind, J. E. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019854962 · Cited by 63
Matesanz, S. E., Curry, C., Gross, B. N., Rubin, A. I., Linn, R. L., Yum, S. W., & Kichula, E. A. (2020) · Journal of Child Neurology · doi:10.1177/0883073820928784 · Cited by 57
Leveraging large genomic datasets to illuminate the pathobiology of autism spectrum disorders
Searles, V. B., Wang, B., & State, M. W. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0768-y · Cited by 56
“Both the use of gene therapy to introduce functional copies of SMN1 into the CNS using an AAV vector [154] as well as the use of antisense oligonucleotides to modulate expression of SMN2 to compensate for loss of SMN1 [155] have proven successful in moderating disease course beginning in infancy.”
BackgroundNeurodegenerative Diseases: Their Onset, Epidemiology, Causes and Treatment
Zaib, S., Javed, H., Khan, I. A., Jaber, F. T., Sohail, A., Zaib, Z., Mehboob, T., Tabassam, N., & Ogaly, H. A. (2023) · ChemistrySelect · doi:10.1002/slct.202300225 · Cited by 59
Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion
Mendell, J. R., Chicoine, L. G., Al-Zaidy, S. A., Sahenk, Z., Lehman, K. J., Lowes, L. P., Miller, N. F., Alfano, L. N., Galliers, B., Lewis, S., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.006 · Cited by 54
“S2), similar to other Phase I clinical trial gene-delivery studies.(6,22) T-cell response to AAVrh74 usually peaked at 1–4 weeks following gene delivery, never reaching SAE level, and there were no corresponding elevations of liver enzymes and no clinical manifestations.”
BackgroundMethodResultInfluentialSelf-citationProgress and challenges of gene therapy for Pompe disease
Ronzitti, G., Collaud, F., Laforet, P., & Mingozzi, F. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.67 · Cited by 51
Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy
Abreu, N. J., & Waldrop, M. A. (2020) · Pediatric Pulmonology · doi:10.1002/ppul.25055 · Cited by 61
“Providers are encouraged to expedite evaluation even early in infancy when there may be minimal symptoms as gene transfer at a young age has been associated with better long‐term motor outcomes at least in Type 1 SMA.(39,45)”
BackgroundMethodInfluentialCombination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1
Oechsel, K. F., & Cartwright, M. S. (2021) · Muscle & Nerve · doi:10.1002/mus.27375 · Cited by 55
“When used singly, all three FDA approved therapies for SMA have shown improvements in motor function and survival time.(2,4,9,10) While the most efficacious combination of the three FDA approved treatments for SMA has not yet been reported, we have found that in our cohort of patients that consecutive onasemnogene and…”
BackgroundSamelson-Jones, B. J., Finn, J. D., Favaro, P., Wright, J. F., & Arruda, V. R. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.001 · Cited by 50
U7 snRNA: A tool for gene therapy
Gadgil, A., & Raczyńska, K. D. (2021) · The Journal of Gene Medicine · doi:10.1002/jgm.3321 · Cited by 54
Dentatorubral-Pallidoluysian Atrophy: An Update
Carroll, L. S., Massey, T. H., Wardle, M., & Peall, K. J. (2018) · Europe PMC (PubMed Central) · doi:10.7916/d8-zw3j-1034 · Cited by 50
Qu, Y., Liu, Y., Noor, A. F., Tran, J., & Li, R. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.250570 · Cited by 56
“The outcomes showed that the 15 patients who received a single intravenous administration of AAV9-AVXS-101 were all alive (an age of at least 20 months) along with improved motor function and increased CHOP INTEND scores up to August 2017 (Mendell et al., 2017).”
Intravenous Infusion of AAV for Widespread Gene Delivery to the Nervous System
Gessler, D. J., Tai, P. W. L., Li, J., & Gao, G. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_8 · Cited by 57
Congenital Disorders of the Human Urinary Tract: Recent Insights From Genetic and Molecular Studies
Woolf, A. S., Lopes, F. M., Ranjzad, P., & Roberts, N. A. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00136 · Cited by 49
Bonanno, S., Marcuzzo, S., Malacarne, C., Giagnorio, E., Masson, R., Zanin, R., Arnoldi, M. T., Andreetta, F., Simoncini, O., Venerando, A., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8020021 · Cited by 50
“Finally, the first scAAV9 gene replacement therapy (Zolgensma®) has been recently approved by the FDA [13].”
BackgroundAlves, C. R. R., Petrillo, M., Spellman, R. G., Garner, R., Zhang, R., Kiefer, M., Simeone, S. D., Sohn, J., Eichelberger, E. J., Rodrigues, E., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.011 · Cited by 53
Alves, C. R. R., Ha, L. L., Yaworski, R., Sutton, E. R., Lazzarotto, C. R., Christie, K. A., Reilly, A., Beauvais, A., Doll, R. M., de la Cruz, D., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01132-z · Cited by 76
“…using an adeno-associated virus (AAV) vector expressing SMN1 such as onasemnogene abeparvovec (Zolgensma, Novartis) presents many challenges 19 , including unknown longevity of expression from the AAV transgene 20 , and potential eventual decay of efficacy in dividing cells due to AAV…”
Iannitti, T., Scarrott, J. M., Likhite, S., Coldicott, I. R. P., Lewis, K. E., Heath, P. R., Higginbottom, A., Myszczynska, M. A., Milo, M., Hautbergue, G. M., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.04.015 · Cited by 49
Self-citationHausott, B., & Klimaschewski, L. P. (2019) · The Anatomical Record · doi:10.1002/ar.24126 · Cited by 53
“Gene replacement therapy has been demonstrated to promote survival of patients with spinal muscular atrophy following a single intravenous infusion of adeno-associated virus containing DNA coding for SMN1 (Mendell et al., 2017).”
BackgroundGusset, N., Stalens, C., Stumpe, E., Klouvi, L., Méjat, A., Ouillade, M.-C., & de Lemus, M. (2021) · Neuromuscular Disorders · doi:10.1016/j.nmd.2021.01.012 · Cited by 51
Day, J. W., Finkel, R. S., Mercuri, E., Swoboda, K. J., Menier, M., van Olden, R., Tauscher-Wisniewski, S., & Mendell, J. R. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.014 · Cited by 48
“Given that anti-AAV9 antibody concentrations are important considerations for the safety and efficacy of AAV9-based therapies, inclusion criteria for the onasemnogene abeparvovec clinical trials and the managed access programs (MAPs) for single-patient investigational new drug (IND) requests from treating physicians i…”
BackgroundSelf-citationXu, L., Yao, S., Ding, Y. E., Xie, M., Feng, D., Sha, P., Tan, L., Bei, F., & Yao, Y. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05661-2 · Cited by 48
“With AAV9’s inherent ability to target motor neurons, AAV9-based Zolgensma ® for the treatment of SMA has been established as the first FDA-approved drug for systemic gene therapy in CNS diseases [171].”
BackgroundPrognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular Atrophy
Baranello, G., Gorni, K., Daigl, M., Kotzeva, A., Evans, R., Hawkins, N., Scott, D. A., Mahajan, A., Muntoni, F., & Servais, L. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2247 · Cited by 55
“Onasemnogene abeparvovec has also been associated with a significant increase in survival in an open‐ label study.(78) This study was identified in the literature search but was excluded during screening as it did not report CIs, statistical significance, or relative measures of treatment effect for subgroups.”
BackgroundResultRibero, V. A., Daigl, M., Martí, Y., Gorni, K., Evans, R., Scott, D. A., Mahajan, A., Abrams, K. R., & Hawkins, N. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2021-0216 · Cited by 59
Pane, M., Berti, B., Capasso, A., Coratti, G., Varone, A., D’Amico, A., Messina, S., Masson, R., Sansone, V., Donati, M. A., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101997 · Cited by 50
MRI-Guided Focused Ultrasound for Targeted Delivery of rAAV to the Brain
Noroozian, Z., Xhima, K., Huang, Y., Kaspar, B. K., Kügler, S., Hynynen, K., & Aubert, I. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-9139-6_10 · Cited by 48
Self-citationStolte, B., Bois, J., Bolz, S., Kizina, K., Totzeck, A., Schlag, M., Kleinschnitz, C., & Hagenacker, T. (2020) · European Journal of Neurology · doi:10.1111/ene.14472 · Cited by 54
“In a cohort of 15 patients with SMA type 1, a single intravenous infusion of onasemnogene abeparvovec-xioi resulted in longer survival and improvement of motor functions when compared to historical cohorts [10].”
ResultHistoric Overview of Genetic Engineering Technologies for Human Gene Therapy
Tamura, R., & Toda, M. (2020) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2020-0049 · Cited by 61
Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing
Hanson, B., Wood, M. J. A., & Roberts, T. C. (2021) · RNA Biology · doi:10.1080/15476286.2021.1874161 · Cited by 54
Gene therapy for spinal muscular atrophy: the Qatari experience
Ali, H. G., Ibrahim, K. O., Elsaid, M. F., Mohamed, R., Abeidah, M., Rawwas, A. O. A., Elshafey, K., Al-Mulla, H., El‐Akouri, K., AlMulla, M., et al. (2021) · Gene Therapy · doi:10.1038/s41434-021-00273-7 · Cited by 53
Ethical Perspectives on Treatment Options with Spinal Muscular Atrophy Patients
Yeo, C. J. J., Simmons, Z., Vivo, D. C. D., & Darras, B. T. (2022) · Annals of Neurology · doi:10.1002/ana.26299 · Cited by 53
“Albeit a rare occurrence, infants may be born with high passive AAV antibody titers (>1:50), but older patients do have a greater risk of high AAV9 antibody titers.(4) Despite good short-term durability thus far, long-term durability and real-world safety of this treatment have not been proven.”
BackgroundCryo-electron Microscopy of Adeno-associated Virus
Stagg, S. M., Yoshioka, C., Davulcu, O., & Chapman, M. S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00936 · Cited by 50
Engineered bacteria launch and control an oncolytic virus
Singer, Z. S., Pabón, J., Huang, H., Sun, W. Y., Luo, H., Grant, K. R., Obi, I., Coker, C., Rice, C. M., & Danino, T. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01476-8 · Cited by 57
“Examples include small DNA viruses such as adeno-associated virus for non-immunogenic tissue targeting, minus-strand RNA viruses such as rabies virus for retrograde neuronal tracing and plus-strand RNA viruses such as the poliovirus-derivative ‘PVSRIPO’ for oncolytic purposes 6–10 .”
Argininosuccinic aciduria fosters neuronal nitrosative stress reversed by Asl gene transfer
Baruteau, J., Perocheau, D. P. B., Hanley, J., Lorvellec, M., Rocha‐Ferreira, E., Karda, R., Ng, J., Suff, N., Diaz, J. F. A., Rahim, A. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05972-1 · Cited by 47
Early Check: translational science at the intersection of public health and newborn screening
Bailey, D. B., Gehtland, L. M., Lewis, M. A., Peay, H. L., Raspa, M., Shone, S. M., Taylor, J. L., Wheeler, A., Cotten, M., King, N. M. P., et al. (2019) · BMC Pediatrics · doi:10.1186/s12887-019-1606-4 · Cited by 50
Impaired kidney structure and function in spinal muscular atrophy
Nery, F. C., Siranosian, J. J., Rosales, I. A., Deguise, M., Sharma, A., Muhtaseb, A. W., Nwe, P. H., Johnstone, A. J., Zhang, R., Fatouraei, M., et al. (2019) · Neurology Genetics · doi:10.1212/nxg.0000000000000353 · Cited by 50
Emerging technologies to study glial cells
Hirbec, H., Déglon, N., Foo, L. C., Goshen, I., Grutzendler, J., Hangen, E., Kreisel, T., Linck, N., Muffat, J., Regio, S., et al. (2020) · Glia · doi:10.1002/glia.23780 · Cited by 47
“The potential and safety of viral vectors is highlighted by the ongoing CNS clinical trials (Cartier et al., 2009; Hudry & Vandenberghe, 2019; Palfi et al., 2018) and the recent approval of Zolgensma (AAV9-SMN) for the treatment of spinal muscular atrophy (Mendell et al., 2017).”
BackgroundBohlen, M. O., McCown, T., Powell, S., El-Nahal, H. G., Daw, T. B., Basso, M., Sommer, M., & Samulski, R. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.196 · Cited by 46
“INTRODUCTION ADENO-ASSOCIATED VIRUS (AAV) vectors have achieved a prominent position in central nervous system (CNS) clinical trials, particularly with respect to the use of AAV serotype 9 (AAV9) for single gene disorders, such as spinal muscular atrophy and giant axon neuropathy.(1,2)”
Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain
Pardridge, W. M. (2020) · Frontiers in Medical Technology · doi:10.3389/fmedt.2020.602236 · Cited by 46
“The first FDA approved AAV gene therapy for the brain is Zolgensma R © (10), which is a scAAV9 encoding the human spinal muscular atrophy (SMN)1 gene.”
BackgroundNew therapies for spinal muscular atrophy: where we stand and what is next
Antonaci, L., Pera, M. C., & Mercuri, E. M. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-04883-8 · Cited by 52
Shoop, W. K., Lape, J., Trum, M., Powell, A., Sevigny, E., Mischler, A., Bacman, S. R., Fontanesi, F., Smith, J., Jantz, D., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00932-6 · Cited by 56
“Successful delivery to the CNS has been demonstrated following intravenous injection of AAV9 in mice 72 , non-human primates 73,74 and humans 75,76 .”
Moyer, T. C., Hoffman, B. A., Chen, W., Shah, I. S., Ren, X., Knox, T. M., Liu, J., Wang, W., Li, J., Khalid, H., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.046 · Cited by 68
“…safety range of AAV treatment 38 and 10 times below the AAV9-based Zolgensma, which has been successfully delivered to infants at 1e14 VG/kg. 5,6 This elevated CNS tropism, together with lower liver transduction, strongly suggests that VCAP-102 could provide a markedly improved therapeutic…”
Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis
Tosolini, A. P., & Sleigh, J. N. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00405 · Cited by 52
“The treatment is safe and well tolerated, and caused improvements in survival, attainment of motor milestones, and motor function when compared with historical SMA type I cohorts (Mendell et al., 2017).”
ResultSerra‐Juhé, C., & Tizzano, E. F. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-019-0415-4 · Cited by 54
Combination therapy with nusinersen and AVXS-101 in SMA type 1
Lee, B. H., Collins, É., Lewis, L., Guntrum, D., Eichinger, K. J., Voter, K. Z., Abdel-Hamid, H. Z., & Ciafaloni, E. (2019) · Neurology · doi:10.1212/wnl.0000000000008207 · Cited by 49
“SMN1 gene replacement with AAV9 (AVXS-101) is under FDA review and has been available under a managed access program since November 2018.(5)”
MethodReldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study
Rudnicki, S. A., Andrews, J. A., Duong, T., Cockroft, B. M., Malik, F. I., Meng, L., Wei, J., Wolff, A. A., Genge, A. L., Johnson, N. E., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-020-01004-3 · Cited by 52
“The gene therapy onasemnogene abeparvovec-xioi is effective in infants and recently gained approval by the US Food and Drug Administration for patients < 2 years of age with SMA [11, 12].”
Backgroundvan Hees, M., Slott, S., Hansen, A. H., Kim, H. S., Ji, H. P., & Astakhova, K. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.003 · Cited by 47
Multicenter Consensus Approach to Evaluation of Neonatal Hypotonia in the Genomic Era: A Review
Morton, S. U., Christodoulou, J., Costain, G., Muntoni, F., Wakeling, E. L., Wojcik, M. H., French, C. E., Szuto, A., Dowling, J. J., Cohn, R. D., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0067 · Cited by 50
“Availability of effective treatments for genetic conditions, such as congenital myasthenic syndromes or spinal muscular atrophy (SMA), 6–8 highlights the importance of a timely diagnosis, and therapies for other hypotonic conditions will probably become available in the future.”
Delivering gene therapy for mucopolysaccharide diseases
Wood, S., & Bigger, B. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.965089 · Cited by 50
“It is currently one of the most popular vectors for gene therapy and is currently being used in clinical trials for neurological conditions (Spinal Muscular Atrophy) and inherited retinal disorders (Choroideremia, Leber’s Congenital Amaurosis, X-Linked Retinitis Pigmentosa), amongst others (MacLaren et al., 2014; Fisc…”
BackgroundPhase I study of liver depot gene therapy in late-onset Pompe disease
Smith, E. C., Hopkins, S., Case, L. E., Xu, M. J., Walters, C. K., DeArmey, S., Han, S.-O., Spears, T. G., Chichester, J. A., Bossen, E. H., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.02.014 · Cited by 48
Smith, T. J., Elmore, Z. C., Fusco, R. M., Hull, J. A., Rosales, A., Martinez, M. L., Tarantal, A. F., & Asokan, A. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.004 · Cited by 45
Advanced micro/nano-electroporation for gene therapy: recent advances and future outlook
Liu, F., Su, R., Jiang, X., Wang, S., Mu, W., & Chang, L. (2024) · Nanoscale · doi:10.1039/d4nr01408a · Cited by 54
Lrig2 and Hpse2, mutated in urofacial syndrome, pattern nerves in the urinary bladder
Roberts, N. A., Hilton, E. N., Lopes, F. M., Singh, S., Randles, M. J., Gardiner, N. J., Chopra, K., Coletta, R., Bajwa, Z., Hall, R. J., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.11.040 · Cited by 43
Tadenev, A. L. D., & Burgess, R. W. (2019) · Mammalian Genome · doi:10.1007/s00335-019-09798-0 · Cited by 55
Messina, S., Frongia, A. L., Antonaci, L., Pera, M. C., Coratti, G., Pane, M., Pasternak, A. E., Civitello, M., Montes, J., Mayhew, A. G., et al. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.10.001 · Cited by 50
Base editing-mediated splicing correction therapy for spinal muscular atrophy
Lin, X., Chen, H., Lu, Y., Hong, S., Hu, X., Gao, Y., Lai, L., Li, J.-J., Wang, Z., Ying, W., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0304-y · Cited by 48
Fatigability in spinal muscular atrophy: validity and reliability of endurance shuttle tests
Bartels, B., de Groot, J. F., Habets, L. E., Wijngaarde, C. A., Vink, W., Stam, M., Asselman, F., van Eijk, R. P. A., & van der Pol, W. L. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-1348-2 · Cited by 51
Piguet, F., de Saint Denis, T., Audouard, E., Beccaria, K., André, A., Wurtz, G., Schatz, R., Alves, S., Sevin, C., Zerah, M., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.105 · Cited by 45
“12 However, the efficacy of brain transduction efficacy may vary with the patient age at treatment.”
InfluentialBroekhoff, T. F., Sweegers, C. C. G., Krijkamp, E., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., Goettsch, W., & Vreman, R. A. (2021) · Value in Health · doi:10.1016/j.jval.2020.09.021 · Cited by 53
Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy
Kotulska, K., Fattal‐Valevski, A., & Haberlová, J. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.726468 · Cited by 47
“The first clinical study with onasemnogene abeparvovec in SMA patients was initiated in 2014 by Mendell et al. at Nationwide Children’s Hospital in Columbus, Ohio (50).”
BackgroundInfluentialAAV‐mediated delivery of an anti‐BACE1 VHH alleviates pathology in an Alzheimer's disease model
Marino, M., Zhou, L., Rincón, M. Y., Callaerts-Végh, Z., Verhaert, J., Wahis, J., Creemers, E., Yshii, L., Wierda, K., Saito, T., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.201809824 · Cited by 36
“In this respect, the recent approval of Zolgensma has revolutionized the treatment of pediatric spinal muscular atrophy (SMA) (Mendell et al, 2017), with significant increases in survival and motor skills reported in patients, following a single systemic injection of vector.”
Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives
Lejman, J., Panuciak, K., Nowicka, E., Mastalerczyk, A., Wojciechowska, K., & Lejman, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021130 · Cited by 58
Gowda, V. L., Atherton, M., Murugan, A., Servais, L., Sheehan, J., Standing, E., Manzur, A. Y., Scoto, M., Baranello, G., Munot, P., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100817 · Cited by 53
Spinal Muscular Atrophy Update in Best Practices
Schroth, M. K., Deans, J., Arya, K., Castro, D., Vivo, D. C. D., Gibbons, M. A., Ionita, C., Kuntz, N. L., Lakhotia, A., Knierbein, E. E. N., et al. (2024) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200310 · Cited by 52
The curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 53
A battery-free nanofluidic intracellular delivery patch for internal organs
Yin, D., Wang, P., Hao, Y., Yue, W. W., Jiang, X., Yao, K., Wang, Y., Hang, X., Xiao, A., Zhou, J., et al. (2025) · Nature · doi:10.1038/s41586-025-08943-x · Cited by 58
“This finding indicated that the therapeutic effects of NanoFLUID-mediated drug delivery are solely enabled by the actuation of the device (Supplementary Video 2).”
Gernoux, G., Gruntman, A. M., Blackwood, M., Zieger, M., Flotte, T. R., & Mueller, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.004 · Cited by 44
“Currently, one way to efficiently manage the cytotoxic immune response and restore gene expression post-vector delivery is transient corticosteroid-based immunosuppression.(29,32)”
Finkel, R. S., Day, J., Vivo, D. C. D., Kirschner, J., Mercuri, E. M., Muntoni, F., Shieh, P. B., Tizzano, E. F., Desguerre, I., Quijano-Roy, S., et al. (2020) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-190451 · Cited by 52
“Contemporary follow-ups from EAP programs [31, 33, 34] or clinical trials [15, 17, 18] do not exceed 2 years and include only patients treated with a single approach.”
BackgroundGene therapy for inherited arrhythmias
Bezzerides, V. J., Prondzynski, M., Carrier, L., & Pu, W. T. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa107 · Cited by 47
Spinal Muscular Atrophy Treatments, Newborn Screening, and the Creation of a Neurogenetics Urgency
Butterfield, R. J. (2021) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2021.100899 · Cited by 51
The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular Atrophy
Edinoff, A. N., Nguyen, L. H., Odisho, A. S., Maxey, B. S., Pruitt, J., Girma, B., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Orthopedic Reviews · doi:10.52965/001c.24934 · Cited by 48
Nanoscale delivery platforms for RNA therapeutics: Challenges and the current state of the art
Rhym, L. H., & Anderson, D. G. (2022) · Med · doi:10.1016/j.medj.2022.02.001 · Cited by 49
Gene Therapy in Orthopaedics: Progress and Challenges in Pre-Clinical Development and Translation
Levings, R. W., Palmer, G. D., Levings, P. P., Dacanay, E. A., Evans, C. H., & Ghivizzani, S. C. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.901317 · Cited by 53
“Importantly, these approved treatments span a wide range of conditions, including B-cell leukemia and lymphoma, melanoma, spinal muscular atrophy (Mendell et al., 2017), Leber congenital amaurosis (Russell et al.”
BackgroundEngineering viral vectors for acoustically targeted gene delivery
Li, H., Harb, M., Heath, J. E., Trippett, J. S., Shapiro, M. G., & Szablowski, J. O. (2024) · Nature Communications · doi:10.1038/s41467-024-48974-y · Cited by 55
“However, the site-speci fi c delivery of common gene vectors such as adeno-associated viruses (AAVs) is typically performed via invasive injections, which limit its applicable scope of research and clinical applications.”
BackgroundStem cell therapeutics and gene therapy for neurologic disorders
Chen, K. S., Koubek, E. J., Sakowski, S. A., & Feldman, E. L. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00427 · Cited by 49
“For example, AAV9 is able to cross the BBB and has a propensity for neurons [205], and the AAV9 capsid is utilized to carry the self-complementary sequence used in onasemnogene abeparvovec [206], mentioned above, as well as a predominance of current gene therapy trials [207].”
BackgroundWalter, L. M., Deguise, M., Meijboom, K. E., Betts, C., Ahlskog, N., van Westering, T. L. E., Hazell, G., McFall, E. R., Kordala, A. J., Hammond, S. M., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.04.024 · Cited by 49
“22 one day pre-gene therapy and for 30 days thereafter (Mendell et al., 2017).”
An observational study of functional abilities in infants, children, and adults with type 1 SMA
Pane, M., Palermo, C., Messina, S., Sansone, V., Bruno, C., Catteruccia, M., Sframeli, M., Albamonte, E., Pedemonte, M., D’Amico, A., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006050 · Cited by 50
Farrar, M. A., Carey, K. A., Paguinto, S.-G., Kasparian, N. A., & Lourenço, R. D. A. (2020) · Patient · doi:10.1007/s40271-020-00415-w · Cited by 48
Smeriglio, P., Langard, P., Querin, G., & Biferi, M. G. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030075 · Cited by 51
“Recent advances in the SMA field have led to the development of therapeutic approaches, aiming to increase the level of SMN protein targeting SMN2 through an antisense (AS) oligonucleotide [14,15] or a pre-mRNA splicing modifier drug [16], as well as inducing the restoration of the SMN protein via gene therapy [17].”
BackgroundTranslating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 48
“Zolgensma—the approved CNS targeting gene therapy for SMA—delivers scAAV9-SMN1 systemically to target motor neurons.(4) However, the high vector dose”
Treatment Options in Congenital Disorders of Glycosylation
Park, J. H., & Marquardt, T. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.735348 · Cited by 46
Metadata
- Authors
- Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L’Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., Braun, L., Likhite, S., Miranda, C., Meyer, K., Foust, K. D., Burghes, A. H. M., & Kaspar, B. K.
- Affiliations
- Abigail Wexner Research Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-02
- Volume
- 377
- Issue
- 18
- Pages
- 1713-1722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2765253110
- Cited by
- 2,381
- References
- 26
- Citations by year
- 2026: 205 · 2025: 232 · 2024: 292 · 2023: 270 · 2022: 289 · 2021: 347 · 2020: 298 · 2019: 246 · 2018: 172 · 2017: 16
- FWCI
- 115.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nationwide Children's Hospital
- AveXis
- Research Institute, Nationwide Children's Hospital
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- spinal muscular atrophy type 1, gene replacement therapy, adeno-associated virus vectors, SMN1, motor function, motor milestones, survival, CHOP INTEND, aminotransferase elevation, prednisolone, treatment efficacy and safety
- MeSH terms
- Dependovirus, Female, Genetic Vectors, Humans, Infant, Infant, Newborn, Infusions, Intravenous, Liver Diseases, Male, Motor Skills, Respiration, Artificial, Spinal Muscular Atrophies of Childhood, Genetic Therapy, Cohort Studies, Nutritional Support, Disease-Free Survival, Survival of Motor Neuron 1 Protein, Historically Controlled Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.